154 related articles for article (PubMed ID: 25427105)
21. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Panzer S; Sunder-Plassmann R; Mannhalter C; Steiner S
Int J Cardiol; 2013 Jun; 166(1):126-31. PubMed ID: 22075408
[TBL] [Abstract][Full Text] [Related]
22. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
[TBL] [Abstract][Full Text] [Related]
23. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
[TBL] [Abstract][Full Text] [Related]
24. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
[TBL] [Abstract][Full Text] [Related]
25. Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study.
Paniccia R; Antonucci E; Maggini N; Miranda M; Romano E; Gori AM; Marcucci R; Prisco D; Abbate R
Ther Drug Monit; 2011 Feb; 33(1):94-8. PubMed ID: 21192314
[TBL] [Abstract][Full Text] [Related]
26. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
27. P2Y12 platelet function assay for assessment of bleeding risk in coronary artery bypass grafting.
Yu PJ; Cassiere HA; Dellis SL; Manetta F; Stein J; Hartman AR
J Card Surg; 2014 May; 29(3):312-6. PubMed ID: 24588751
[TBL] [Abstract][Full Text] [Related]
28. Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.
Bae JP; Candrilli SD; Fortenberry J; Meyers JL; Jakubowski JA; Drenning D
Hosp Pract (1995); 2014 Oct; 42(4):7-15. PubMed ID: 25502126
[TBL] [Abstract][Full Text] [Related]
29. Correlation Between the VerifyNow P2Y
Uematsu K; Sakayori T; Ishida H; Omori Y; Kitano K; Matsubara H; Enomoto Y
Ann Clin Lab Sci; 2020 Jul; 50(4):490-496. PubMed ID: 32826246
[TBL] [Abstract][Full Text] [Related]
30. Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
Patti G; Mangiacapra F; Ricottini E; Cannatà A; Cavallari I; Vizzi V; D'Ambrosio A; Dicuonzo G; Di Sciascio G
Am J Cardiol; 2013 Jun; 111(12):1739-44. PubMed ID: 23538022
[TBL] [Abstract][Full Text] [Related]
31. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E
J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370
[TBL] [Abstract][Full Text] [Related]
32. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes.
Larsen PD; Holley AS; Sasse A; Al-Sinan A; Fairley S; Harding SA
Thromb Res; 2017 Apr; 152():14-19. PubMed ID: 28213102
[TBL] [Abstract][Full Text] [Related]
34. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
[TBL] [Abstract][Full Text] [Related]
35. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Park DW; Ahn JM; Song HG; Lee JY; Kim WJ; Kang SJ; Yun SC; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Am Heart J; 2013 Jan; 165(1):34-42.e1. PubMed ID: 23237131
[TBL] [Abstract][Full Text] [Related]
36. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.
Kim IS; Jeong YH; Kang MK; Koh JS; Park Y; Hwang SJ; Kwak CH; Hwang JY; Kim S
J Thromb Thrombolysis; 2010 Nov; 30(4):486-95. PubMed ID: 20449634
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Tsigkas G; Damelou A; Theodoropoulos KC; Makris G; Gizas V; Kassimis G; Davlouros P; Hahalis G
Thromb Res; 2013 Apr; 131(4):333-7. PubMed ID: 23481479
[TBL] [Abstract][Full Text] [Related]
38. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
39. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
[TBL] [Abstract][Full Text] [Related]
40. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation.
Park DW; Lee SW; Yun SC; Song HG; Ahn JM; Lee JY; Kim WJ; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
J Am Coll Cardiol; 2011 Dec; 58(25):2630-9. PubMed ID: 22152948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
